This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in
INTRODUCTION
Lung cancer represents a major health burden. Many affected individuals present with advanced disease and are candidates for palliative systemic therapy. Historically, all patients with advanced non-small-cell lung cancer (nsclc) would receive similar therapy, in which platinum doublets were recommended as initial (first-line) therapy 1,2 , pemetrexed 3 or docetaxel 4, 5 as second-line therapy, and erlotinib as second-or third-line therapy 6, 7 .
Significant changes have taken place in the approach to the treatment of advanced nsclc since 2010. Treatment algorithms are now heavily influenced by the histologic subtype of nsclc 8 , and multiple trials have examined the sequence of subsequent lines of therapy [epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) vs. chemotherapy]. More importantly, the discovery of molecular abnormalities such as mutations of the EGFR gene 9, 10 and translocations of the ALK 11 gene have identified a group of patients who appear to derive significantly greater benefit from molecularly targeted therapies.
METHODS
Four clinical members of the Program in EvidenceBased Care's Lung Cancer Disease Site Group and one methodologist selected and reviewed evidence related to egfr tkis in nsclc. The body of evidence in this review primarily encompasses mature randomized controlled trial data.
Literature Search Strategy
The medline (2006 to March 2014), embase (2006 to March 2014), and Cochrane Library (March 2014) databases were searched for published practice guidelines, systematic reviews, and randomized clinical trials. Reference lists of papers and review articles were scanned for additional citations. The Canadian Medical Association Infobase (https:// www.cma.ca/En/Pages/clinical-practice-guidelines.aspx), the U.S. National Guidelines Clearinghouse (http://www. guideline.gov/), and other Web sites were searched for existing evidence-based practice guidelines. The American Society of Clinical Oncology conference proceedings from 2007 to 2013 were also searched. Search terms indicative of nsclc, gefitinib (Iressa: AstraZeneca, Mississauga, ON), erlotinib (Tarceva: Genentech, San Francisco, CA, U.S.A.), afatinib, dacomitinib, and icotinib were used. Articles published before 2006 and included in this version of the systematic review were found using the search strategy described in the previous version of the guideline 6 . Only fully published articles from the previous version of this systematic review were included.
Study Selection Criteria
Publications were included in the review if they were metaanalyses or randomized trials (phase ii or iii) comparing gefitinib, erlotinib, afatinib, dacomitinib, or icotinib alone or in combination with chemotherapy with placebo, best supportive care, or chemotherapy; or comparing various doses or schedules of gefitinib, erlotinib, afatinib, dacomitinib, or icotinib; and fully published papers or published abstracts of trials in any language that reported at least one of the following outcomes by treatment group: symptom control, quality of life, tumour response rate, survival, or toxicity.
Publications were excluded from the review if they were pilot trials, dose-escalation trials, or case series (including expanded access programs); letters and editorials that reported clinical trial outcomes; or conference abstracts before 2007.
Synthesizing the Evidence
When clinically homogenous results from two or more trials were available, the data were pooled using the Review Manager software (RevMan 5.1.6) provided by the Cochrane Collaboration. Because hazard ratios (hrs), rather than the number of events at a certain time point, are the preferred statistic for pooling time-to-event outcomes 12 , hrs were extracted directly from the most recently reported trial results. The variances of the hr estimates were calculated from the reported confidence intervals (cis) using the methods described by Parmar et al. 12 . A random effects model was used for all pooling.
Statistical heterogeneity was calculated using the chi-square test for heterogeneity and the I 2 percentage. A probability level for the chi-square statistic less than or equal to 10% (p ≤ 0.10) or an I 2 greater than 50% (or both) were considered indicative of statistical heterogeneity. Results are expressed as hrs with 95% cis. A hr greater than 1.0 indicates that patients receiving gefitinib, erlotinib, afatinib, dacomitinib, or icotinib had a higher probability of experiencing an event; conversely, a hr less than 1.0 suggests that patients receiving erlotinib or gefitinib had a lower probability of experiencing an event.
RESULTS

Literature Search Results
Of the 3633 English and foreign-language studies identified, ninety-six randomized trials met the predefined eligibility criteria for the present systematic review. Of those trials, sixty-six were fully published reports, and thirty were in abstract form, including four updates to fully published trials. Slide presentations associated with abstract trial reports were also included if the presentations were publicly available on meeting Web sites and if they provided additional data. No relevant systematic reviews that answered our research questions were identified.
Outcomes
This report separately considers three populations of nsclc patients (unselected, clinically selected, and molecularly selected). In the unselected group, any nsclc patient was allowed to participate in the trial as long as the other trial eligibility criteria were met in the absence of molecular testing. In the clinically selected group, patients were selected based on clinical characteristics predictive of an EGFR mutation such as Asian ethnicity, adenocarcinoma histology, female sex, smoking status, or age. In the molecularly selected group, patients were included if their tumours tested positive for an EGFR mutation.
First-Line Treatment
Unselected Populations: EGFR Inhibitor Compared with Chemotherapy: Six fully published papers and three abstracts compared an egfr inhibitor with platinum-based chemotherapy. Most of the trials were small, with fewer than 100 patients per arm. Only the torch trial appeared to have a sufficient number of participants to provide meaningful information on overall survival (os) 13 (Table i) . The findings of the trials suggest that first-line therapy with an egfr tki is inferior to chemotherapy in an unselected population of nsclc patients.
Response rate was not reported in three studies. In one study, the response rate favoured the egfr inhibitor 21 , and in four studies, it favoured chemotherapy 13, 14, [19] [20] [21] . The study by Reck et al. 19 found a significantly higher response rate in patients randomized to chemotherapy (p = 0.0001).
The results show improved progression-free survival (pfs) for patients randomized to chemotherapy. Median pfs was similar in two trials 14, 18 . In one trial, pfs was longer in the egfr inhibitor group: 4.57 months for erlotinib versus 2.53 months for vinorelbine (hr: 0.6444; 95% ci: 0.4325 to 0.9601; p = 0.0308) 21 . In five trials, pfs was longer in the chemotherapy group 13, 15, 17, 19, 20 . Several of the trials found that pfs significantly favoured chemotherapy 13, 15, 19 . One trial examined time to progression and found that it was longer with chemotherapy, but not significantly so 20 . One trial reported nonsignificant improvements in os in the egfr inhibitor group 21 . In seven trials, os was prolonged with chemotherapy [13] [14] [15] [17] [18] [19] [20] . In the largest trial (torch), os was significantly worse for patients randomized to erlotinib 13 . Those findings suggest that initial therapy with an egfr tki in an unselected population of patients with advanced nsclc could be inferior treatment.
Quality of life and symptom control were discussed in three trials 14, 17, 21 . In the trial by Crino et al. 14 , the gefitinib group scored higher on all four of the quality of life assessment tools. The trials by Agarwal et al. 17 and Chen et al. 21 found no difference in quality of life, although the patients in the erlotinib group in the Chen et al. trial reported significantly better physical well-being.
The most significant toxicities from egfr inhibitors are diarrhea and rash. Most other adverse effects were mild and occurred at similar rates in all trials, with the exception of neutropenia, which occurred more commonly in the chemotherapy arm.
EGFR Inhibitor Plus Chemotherapy Compared with Chemotherapy Alone:
Eight trials examined the use of a first-line egfr inhibitor plus chemotherapy compared with chemotherapy alone in unselected patients. Four trials evaluated continuous egfr tki plus chemotherapy, three trials evaluated intermittent egfr tki (intercalated), and one trial evaluated combination chemotherapy plus an egfr tki compared with sequential egfr tki followed by chemotherapy.
The data showed no benefit for the addition of an egfr tki to first-line chemotherapy, although the trial of intercalated egfr tki showed an improvement in pfs. No significant differences in the response rate were observed in four trials involving more than 4000 patients [22] [23] [24] [25] (Table i). In three additional trials, the response rate favoured the egfr inhibitor group [22] [23] [24] [25] [27] [28] [29] . In the trial by Riely et al. 28 , the response rate was the highest (34%) for erlotinib 1500 mg daily, followed by paclitaxel and carboplatin chemotherapy. The response rate was 18% in the arm in which the dose of erlotinib was 150 mg, and 28% in the arm in which paclitaxel and carboplatin was followed by erlotinib 1500 mg daily.
Three trials reported pfs, with all reporting a longer pfs in the combined egfr inhibitor and chemotherapy groups 23, 27, 29 . Statistical significance was reported in two of the trials, which both favoured the egfr plus chemotherapy groups 27, 29 . Four trials reported time to progression 22, 24, 25, 28, 34 . The intact 1 and 2, tribute, and talent trials all showed no significant difference in time to progression across all arms 22, 24, 25 . The trial by Riely et al. 28 did not show an increase in time to progression when erlotinib daily doses of 150 mg and 1500 mg were compared (both followed by paclitaxel and carboplatin): in both groups, time to progression was 4 months. The combination of paclitaxel and carboplatin followed by erlotinib 1500 mg daily showed a 1-month increase in time to progression. An unplanned subgroup analysis by mutation status for patients in the tribute trial with available tissue showed an increase in time to progression for erlotinib plus paclitaxel and carboplatin (12.5 months) compared with chemotherapy alone (6.6 months), but that difference did not reach significance (p = 0.092) 24 .
There was no clear improvement in os with the addition of an egfr tki to chemotherapy. Statistical significance was not reached in any trial. In the trial by Riely et al. 28 , survival was greatest with erlotinib 1500 mg daily followed by paclitaxel and carboplatin: 15 months compared with 10 months for both erlotinib 150 mg daily followed by paclitaxel and carboplatin, and paclitaxel and carboplatin followed by erlotinib 1500 mg daily. The fast-act ii trial observed a trend toward longer os favouring the chemotherapy plus erlotinib arm (hr: 0.78; 95% ci: 0.60 to 1.02; p = 0.069) 29 . Those results do not support the addition of an egfr tki to platinum-based chemotherapy. Toxicities were similar between the groups, with the exception of diarrhea and skin disorders, which occurred more frequently in the egfr inhibitor groups.
Other First-Line Trials: Six additional trials evaluating various approaches of egfr tki and chemotherapy were identified; none showed evidence of improved os. In two trials evaluating an egfr tki compared with placebo in patients not suitable for chemotherapy, no clear differences in pfs or os were observed ( Table i) . Statistical significance was reached in the trial by Lee et al. 35 for pfs, but neither trial showed a difference in os 30, 35 . Quality of life in the Goss et al. 30 trial was not different between the two arms. For gefitinib, the rates of improvement in quality of life were 21.1% [by the Functional Assessment of Cancer Therapy-Lung (fact-L)], 15.8% (by the Trial Outcome Index), 32.9% (by the lung cancer subscale of the fact-L), and 28.3% (by the Pulmonary Symptom Improvement test); for placebo, the corresponding rates were 20%, 13.8%, 30.89%, and 28.3% respectively.
In the 3-arm trial by Stinchcombe et al. 32 , sequential and concurrent gemcitabine plus erlotinib both led to higher response rates and longer pfs than did erlotinib alone, although the differences were not statistically significant. The longest os was observed in patients receiving sequential chemotherapy followed by erlotinib. No clear difference in quality of life was evident using the Trial Outcome Index (p = 0.76), the lung cancer subscale of the fact-L (p = 0.85), or the fact-L (p = 0.57).
The two trials that compared an egfr inhibitor plus a targeted agent with a targeted agent and chemotherapy showed mixed results 31, 33 . The trial by Boutsikou et al. 34 used a factorial design to evaluate the addition of erlotinib and bevacizumab to cisplatin and docetaxel. No significant improvement in os was observed, although the response rate was highest in the chemotherapy plus erlotinib arm. Time to progression was significant and longest in the combination arm (p = 0.001).
Clinically Selected Populations:
Three studies that compared an egfr inhibitor with chemotherapy in clinically selected patients in the first-line setting (Table ii) were identified. A large proportion of the patients in these trials crossed over to the alternative therapy at progression. The ipass trial demonstrated significant improvements in response rate and pfs, but no difference in os 36 . No significant outcome differences were observed in the other two trials 38, 39 . Subgroup analyses for the ipass and First-signal trials were done for patients with tumour samples available for EGFR mutation testing 36, 38 . In the First-signal trial, EGFR mutation-positive patients treated with gefitinib (compared with those treated with gemcitabine and cisplatin) showed a higher overall response rate (84.6% vs. 37.5%, p = 0.002) and a trend toward longer pfs (hr: 0.544; 95% ci: 0.269 to 1.100; p = 0.086). The mutation-negative patients in the gemcitabine and cisplatin arm (compared with the those in the gefitinib arm) showed a trend toward a higher overall response rate (51.9% vs. 25.9%, p = 0.051) and longer pfs (hr: 1.419; 95% ci: 0.817 to 2.466; p = 0.226). The treatment arms showed no significant differences in os according to EGFR mutation status (mutation-positive subgroup hr: 1.043; 95% ci: 0.498 to 2.182; mutationnegative subgroup hr: 1.000; 95% ci: 0.523 to 1.911; and mutation-unknown subgroup hr: 0.880; 95% ci: 0.639 to 1.210) 38 .
Findings were similar in the ipass trial: pfs was significantly longer for patients in the mutation-positive subgroup receiving gefitinib than for those receiving carboplatin-paclitaxel (hr: 0.48; 95% ci: 0.36 to 0.64; p < 0.001). In the mutation-negative subgroup, pfs was significantly shorter in patients receiving gefitinib than in those receiving carboplatin-paclitaxel (hr: 2.85; 95% ci: 2.05 to 3.98; p < 0.001). Results in the subgroup with unknown EGFR mutation status were similar to those for the overall population. The os with gefitinib therapy trended longer in the mutation-positive subgroup (hr: 0.78; 95% ci: 0.50 to 1.20) than in the mutation-negative subgroup (hr: 1.38; 95% ci: 0.92 to 2.09) or in the mutation-unknown subgroup (hr: 0.86; 95% ci: 0.68 to 1.09) 36 , which suggests that the benefit of first-line therapy with an egfr tki is limited to patients with tumours known to harbour an EGFR mutation. Clinical characteristics should not be used to select patients for first-line egfr tki therapy.
One trial evaluated the combination of an egfr tki plus chemotherapy compared with an egfr tki alone in clinically selected patients. The response rate was greater in the egfr inhibitor plus chemotherapy arm; however, no significant differences in pfs (p = 0.1988) or os 40 were observed. Adverse effects were consistent with those associated with chemotherapy and egfr inhibitors 40 .
Three additional trials compared the combination of an egfr tki plus chemotherapy with chemotherapy alone in clinically selected patients. The addition of gefitinib to cisplatin and pemetrexed resulted in a trend toward longer pfs, but no improvement in os 43 . No clear benefit was observed in the other two trials evaluating the addition of gefitinib to carboplatin and paclitaxel 41 or of erlotinib to gemcitabine 42 .
Results for symptom control and quality of life were addressed in two studies. In the ipass trial, statistical and clinically relevant improvements in quality of life were associated with the use of the egfr inhibitor 36 . The First-signal trial found significant differences in physical (p < 0.001) and social functioning (p = 0.013) favouring gefitinib. No significant differences in emotional and cognitive functioning were observed 38 .
Adverse effects were consistent with those known for egfr inhibitors and chemotherapy. Table iii ). Six trials selected patients with tumours harbouring an EGFR mutation. A meta-analysis of this group of patients was performed because the patients were homogenous, and the treatment comparators were platinum-based chemotherapy regimens. All six trials observed higher response rates favouring the egfr inhibitor group. Three of the trials (Mitsudomi et al. 46 , Zhou et al. 48 and Yang et al. 51 ) found the results to be statistically significant (p < 0.0001).
In every trial, pfs was also statistically significant and favoured the egfr inhibitor 44, 46, 48, [50] [51] [52] . A meta-analysis [ Figure 1(A) ] demonstrated a statistically significant improvement in pfs (hr: 0.35; 95% ci: 0.28 to 0.45; p < 0.00001). However, the I 2 is high at 80%, which shows considerable statistical heterogeneity. In each of the subgroup analyses (different egfr inhibitors), the I 2 also remains high. The cause of the heterogeneity remains unknown at this time.
The addition of the subgroup analyses from both the ipass and First-signal trials in patients with a known EGFR mutation status 36, 38 One additional study compared an egfr inhibitor plus chemotherapy with an egfr inhibitor alone in patients with egfr protein overexpression or increased gene copy number 53 . No clear recommendation can be made from that trial. Response rate and pfs were higher in the egfr plus chemotherapy group, but os favoured the egfr-inhibitoralone group The most significant toxicity was skin rash, which occurred in slightly higher numbers in the egfrinhibitor-alone group 53 .
Symptom control and quality of life were discussed in the Yang et al. 51 and Wu et al. 52 studies. A significant delay in time to deterioration of the cancer-related symptoms of cough (hr: 0.60; p = 0.0072) and dyspnea (hr: 0.68; p = 0.0145) was seen with the egfr inhibitor afatinib 51 . A higher proportion of patients in the afatinib group experienced a significantly longer time to deterioration (hr: 0.56; 95% ci: 0.41 to 0.77; p = 0.0002) 52 .
The adverse effects were consistent with those found with egfr inhibitors and chemotherapy.
Second-Line Treatment
Unselected Populations: EGFR Inhibitor Compared with Chemotherapy: Ten studies [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] compared an egfr inhibitor with chemotherapy (docetaxel or pemetrexed) in second-line treatment (Table iv) . None of the trials incorporated a planned crossover to the other agent at the time of progression. However, at progression, patients were permitted to receive the alternative treatment to which they were assigned. No significant difference in response rate was observed in six of the ten studies 54, 55, 57, [59] [60] [61] 63 . In three of the four studies conducted in Asian populations, the egfr inhibitor was associated with a significantly higher response rate 56, 58, 63 .
The foregoing trials underwent meta-analysis for pfs and os because they addressed similar questions and included clinically homogenous populations [ Figure 3(A,B) ].
(Three of the studies did not provide enough data to be included in the analysis 54, 57, 59 .) No difference in pfs was observed between egfr tki and chemotherapy (hr: 0.99; 95% ci: 0.87 to 1.312; p = 0.83). The I 2 in this analysis was still high at 54%, which shows evidence of statistical heterogeneity.
Biomarker studies performed in the interest trial demonstrated that egfr protein expression, gene copy number, and mutation status, and KRAS mutation status were not predictive of any difference in os for either gefitinib or docetaxel 68 . For patients treated with gefitinib, EGFR mutation status predicted a longer pfs (hr: 0.16; 95% ci: 0.05 to 0.49; p = 0.001). However, the overall results suggest that second-line therapy with an egfr tki or with chemotherapy are both reasonable alternatives.
Similar results were observed for os. A meta-analysis showed no difference in os for second-line egfr tki or chemotherapy [hr: 1.02; 95% ci: 0.95 to 1.09; p = 0.56; Figure 3(B) ]. There did not appear to be significant heterogeneity between the trials for os (I 2 : 0%).
Four studies evaluated symptom control and quality of life. All four found that the use of an egfr inhibitor improved both symptom control and quality of life 54, 56, 58, 60 . Adverse effects were consistent with those associated with egfr inhibitors and chemotherapy.
EGFR Inhibitor Alone Compared with EGFR Inhibitor Plus
Chemotherapy: Five studies compared an egfr inhibitor alone with an egfr inhibitor (concurrent or intercalated) plus chemotherapy. Three of those trials had small patient numbers [64] [65] [66] .
The response rate showed no clear improvement with an egfr tki combined with another agent than with an egfr tki alone (Table iv) . In several trials, small improvements in pfs were noted in favour of the combination arm, but no statistically significant differences were observed [64] [65] [66] [67] 69 . Overall survival followed a similar pattern. All but one of the studies 65 showed that os was longer with an egfr inhibitor plus another agent; in one study, the difference was statistically significant 69 . However, these reports come from small, inadequately powered trials, and so it is not possible to draw any real conclusions from the data.
Symptom control and quality of life were evaluated in the two studies by Chen and colleagues 64, 66 . Using the Lung Cancer Symptom Scale, both studies found no difference in symptoms between the two groups. Adverse effects were consistent with those known for egfr inhibitors and chemotherapy. 71, 79 , some favoured the combination arm 70, 78, [82] [83] [84] [85] [86] , and some found no difference between groups 76, 77 . Progression-free survival followed the same trend as response rate. A number of trials demonstrated improved pfs for the combination of an egfr inhibitor and a targeted agent. However, none of the trials demonstrated any statistically significant improvements in os 74 . Despite the heterogeneous nature of the trials, it is reasonable to conclude that no available evidence currently supports the combination of erlotinib with another targeted agent.
Symptom control and quality of life were reported in two studies. The study by Scagliotti et al. 82 also found no statistical difference in the mean health index score on the EQ-5D (EuroQoL, Rotterdam, Netherlands) between treatment groups (p = 0.3373). The study by Natale et al. 76 found that scores on the European Organisation for Research and Treatment of Cancer's 30-question Quality of Life Questionnaire was similar between the groups: erlotinib 80% and vandetanib 82%. Adverse effects were in line with those commonly associated with egfr inhibitors and chemotherapy.
EGFR Inhibitor Plus Chemotherapy Compared with Chemotherapy Alone:
One study of 165 patients examined the use of an egfr inhibitor plus chemotherapy compared with chemotherapy alone (Table vi) . That study demonstrated a greater response rate and longer pfs for chemotherapy plus an egfr inhibitor. The result for pfs was significant (hr: 0.63; 95% ci: 0.44 to 0.90; p = 0.005). In addition, os was prolonged in the combination arm, and that result was significant (hr: 0.68; 95% ci: 0.47 to 0.98; p = 0.019) 87 . Given the small size of the trial, the evidence is insufficient to recommend the combination of an egfr tki plus chemotherapy. 90 , evaluated the association between os and EGFR mutation status, egfr protein expression, and EGFR gene copy number. Survival was longer in the erlotinib group than in the placebo group when egfr protein was overexpressed (hr: 0.68; 95% ci: 0.49 to 0.95; p = 0.02).
EGFR Inhibitor Compared with
Symptom control and quality of life were addressed in two studies 7, 88 . Time to deterioration of symptoms of cough (p = 0.04), dyspnea (p = 0.03), and pain (p = 0.04) was prolonged and significant with erlotinib in the study by Shepherd et al. 7 . Symptom improvement was significant with gefitinib in the study by Thatcher et al. 88 (p = 0.019). Adverse effects were also in line with those associated with use of egfr inhibitor.
EGFR Inhibitor Compared with EGFR Inhibitor:
Five studies compared egfr inhibitors or dosing of the same egfr inhibitor. The ideal 1 and 2 trials compared two dose levels of gefitinib and found no difference in any of the reported outcomes (Table vi) . Similarly, the icogen trial comparing gefitinib with icotinib and a second trial comparing gefitinib with erlotinib reported no difference in outcomes. A randomized phase ii trial comparing dacomitinib with erlotinib demonstrated a significant improvement in response rate and pfs favouring dacomitinib and a trend toward improvement in os 94 . However, those findings require confirmation in a phase iii trial.
Quality of life was addressed in the two ideal studies. No differences in symptom response were evident for the different doses of gefitinib 91, 92 . Adverse effects were consistent with those known for egfr inhibitors. The adverse effects were slightly elevated with gefitinib 500 mg daily.
Clinically Selected Populations: EGFR Inhibitor Compared with Chemotherapy:
Two trials compared pemetrexed with an egfr inhibitor as second-line therapy in neversmokers (Table vii) . The overall response rate was significantly higher for gefitinib (30.1% vs. 14.9%, p < 0.001) 96 . Progression-free survival was significantly longer for patients randomized to gefitinib (9.4 months vs. 2.9 months, p = 0.010) and also for patients randomized to a combination of erlotinib and pemetrexed (7.4 months vs. 3.8 months for erlotinib and 4.4 months for pemetrexed alone; hr: 0.57; 95% ci: 0.40 to 0.81; p = 0.002) 97 . However, the survival rates were nonsignificantly different (p = 0.89) 96, 97 .
One study examined the use of gefitinib in patients with nonsquamous disease in the second-line setting (Table vii) 98 . No difference in the response rate was observed; however, pfs was significantly better with pemetrexed (4.8 months vs. 1.6 months with gefitinib; hr: 0.51; 95% ci: 0.36 to 0.73; p < 0.001) 98 . Overall survival was not yet reached for this trial.
Third-or Fourth-Line EGFR Inhibitor Compared with Placebo:
The lux-Lung 1 trial evaluated afatinib in patients who had received 1 or 2 prior chemotherapy treatments and, in a selected population of patients, also gefitinib or erlotinib ( Table vii) . The response rates were 7% for afatinib and 0.5% for placebo. A significant improvement in pfs was evident for patients randomized to afatinib (3.3 months vs. 1.1 months, p < 0.0001). However, no difference in the primary outcome of os was observed (10.8 months vs. 12 months, p = 0.74). Adverse effects were consistent with those associated with egfr inhibitors 99 . There is therefore currently no evidence that further therapy with an egfr tki in patients who have already received gefitinib or erlotinib improves os.
Molecularly Selected Populations: EGFR Inhibitor Compared with Chemotherapy:
One study compared the use of an egfr inhibitor with the use of chemotherapy in patients known to be EGFR wild-type 100 . The trial specifically excluded crossover to the other treatment at the time of progression. Compared with erlotinib, docetaxel was associated with an improved pfs (hr: 0.71; 95% ci: 0.53 to 0.95; p = 0.02). The primary outcome in the trial was os, which was also significant for docetaxel at 8. 102 . Adverse effects were in line with those associated with egfr inhibitors.
EGFR Inhibitor Compared with EGFR Inhibitor:
One study compared egfr inhibitors in molecularly selected patients 103 (Table viii) . Response rate and pfs were higher in the gefitinib group than in the erlotinib group. Significance was not reached for pfs (p = 0.336). Adverse effects were in line with those associated with egfr inhibitors 103 .
Maintenance
Unselected Populations: EGFR Inhibitors: In recent years, attempts to improve the survival of patients with advanced nsclc have led to considerable interest in CR = complete response; PR = partial response; PFS = progression-free survival; ORR = overall response rate; HR = hazard ratio; CI = confidence interval; BSC = best supportive care.
evaluating maintenance therapies. Trials have evaluated continuing a drug ("continuation maintenance") or switching to another drug ("switch maintenance"). Five studies have examined egfr inhibitors in unselected patients in the switch-maintenance setting, but none of those trials mandated the use of an egfr tki in the placebo arm at the time of disease progression.
One study compared an egfr inhibitor with chemotherapy in the maintenance setting (Table ix) . Bylicki et al. 107 randomized patients to maintenance therapy with erlotinib, gemcitabine, or observation. In the observation group, patients received no treatment. No clear improvement in pfs was observed for either erlotinib or gemcitabine. No significant difference in os was observed, but a trend toward improved survival was evident in both the erlotinib group (hr: 0.80; 95% ci: 0.61 to 1.05; p = 0.13) and the gemcitabine group (hr: 0.81; 95% ci: 0.61 to 1.07; p = 0.109) compared with the observation group. No outstanding adverse effects occurred in the erlotinib group 107 .
Four trials evaluated an egfr tki as maintenance therapy. A clear improvement in pfs was observed, but only one trial showed a significant improvement in os. One Japanese trial compared 6 cycles of a platinum doublet with 3 cycles of a platinum doublet followed by gefitinib until progression. A significant improvement in pfs was observed, but no significant improvement in os 105 . A second trial compared bevacizumab plus erlotinib with bevacizumab alone in patients treated with 4 cycles of carboplatin, paclitaxel, and bevacizumab. A significant improvement in pfs (4.8 months vs. 3.7 months, p < 0.001) was observed 108 . Two additional studies evaluated an egfr tki as maintenance therapy, comparing it with a placebo control, after 4 cycles of a platinum doublet. Both studies showed significant improvements in pfs. The saturn trial, which evaluated maintenance erlotinib, showed a significant improvement in os, although the difference in median survival was only 1 month 104 . In a preplanned subgroup analysis of the saturn trial, patients with stable disease after first-line chemotherapy experienced a greater os benefit with maintenance erlotinib (median survival: 11.9 months for erlotinib vs. 9.6 months for placebo; hr: 0.72; 95% ci: 0.59 to 0.89; p = 0.0019) than did patients who experienced a previous complete or partial response (12.5 months for erlotinib vs. 12.0 months for placebo; hr: 0.94; 95% ci: 0.74 to 1.20; p = 0.618) 104 . Zhang et al. 106 showed a similar effect on os with maintenance gefitinib, although the difference was not statistically significant (hr: 0.84; 95% ci: 0.62 to 1.14).
Quality of life and adverse effects were assessed in two studies. The saturn study showed no statistically significant difference in quality of life (fact-L questionnaire) 106 study showed that, based on the fact-L questionnaire, median time to worsening of lung cancer symptoms was 4.3 months with gefitinib and 2.3 months with placebo.
Adverse effects were consistent with what would be expected for gefitinib and erlotinib (increase in rash and diarrhea).
Clinically Selected Populations: EGFR Inhibitors:
One fully published study 109 examined the use of an egfr inhibitor in clinically selected patients in the maintenance setting. Table ix presents the study characteristics.
The trial randomized 49 patients to gefitinib or pemetrexed, making it underpowered to provide meaningful data on efficacy. Median pfs was associated with a hr of 0.191 (95% ci: 0.074 to 0.0497), and os was prolonged in the pemetrexed and optional-cisplatin group (hr: 2.151; 95% ci: 0.826 to 5.599). Adverse effects were consistent with those associated with egfr inhibitors and chemotherapy.
DISCUSSION AND CONCLUSIONS
Analysis of early trials evaluating egfr tkis suggested that clinical characteristics such as Asian ethnicity, female sex, non-smoking status, and adenocarcinoma were associated with a higher likelihood of response. Those characteristics were subsequently used in clinical trials to enrich the population of patients who might benefit from those drugs. However, it is now clear that the population of patients who derive the greatest benefit from egfr tkis are patients with tumours harbouring activating mutations of the EGFR gene. Nevertheless, the available data still support a more modest benefit from egfr tkis in unselected populations of nsclc patients. The present systematic review provides guidance for the use of egfr tki therapy in advanced nsclc and, in particular, whether there are subpopulations of nsclc patients in whom the sequence of therapy should be different.
In the first-line setting, data about the efficacy of egfr tkis compared with the efficacy of platinum-based chemotherapy are inconsistent. The largest trial in that setting, torch 13 , showed a statistically significantly inferior os for patients receiving first-line egfr tki therapy, and those agents are therefore not recommended in the first-line setting for an unselected population of nsclc patients. Studies selecting patients based on clinical characteristics such as Asian ethnicity, smoking status, and adenocarcinoma histology have also had mixed results. Although selection strategies are designed to increase the proportion of patients with an EGFR mutation, data from the ipass trial show that, when clinical characteristics are used to select patients, only 60% typically have EGFR mutations 36 . Significantly worse response rates and pfs are observed for patients with wildtype EGFR who are treated with first-line gefitinib. The use of clinical characteristics such as ethnicity, sex, smoking status, and histology cannot therefore be recommended in selecting patients for first-line therapy with an egfr tki. No available data support combining an egfr tki with platinumbased chemotherapy. However, high-quality evidence from multiple randomized clinical trials shows that an egfr tki is the preferred initial therapy (in preference to a platinum doublet) for patients with an activating mutation of the EGFR gene. Such treatment is associated with a higher likelihood of response, longer pfs, and improved quality of life, but with no clear difference in os. Many patients randomized in the trials to platinum-doublet chemotherapy crossed over to an egfr tki as subsequent therapy. The likely effect of that crossover was to dilute any survival difference between the groups, making comparisons of os less informative.
Cohort data from the Spanish Lung Cancer Group 30 report on egfr tkis given as either first-or second-line therapy in patients with EGFR mutations. The benefit appears to be similar in both groups, so that even though the comparison was nonrandomized, the consensus is that crossover explains the difference. Although the trials show statistical heterogeneity, no available data suggest that one egfr tki is superior to another in this setting. Some trials included only patients with exon 19 deletion and exon 21 L858R point mutation; other trials such as lux-Lung 3 included other less common mutations. Those considerations might be a factor in making a choice of agent. However, the decision to use gefitinib, erlotinib, or afatinib is largely influenced by concerns about their toxicity or cost.
Data from the ncic br.21 trial of erlotinib compared with placebo demonstrate a modest improvement in survival and quality of life with erlotinib in patients who are no longer candidates for further chemotherapy 7 . Based on those data, erlotinib was recommended as a last line of therapy in the previous version of this guideline. However, multiple trials of second-line therapy comparing an egfr tki with chemotherapy have now been reported. A metaanalysis of the data demonstrates similar pfs and os. Level 1 evidence therefore now shows that there is no preferred sequence for second-line egfr tki or second-line chemotherapy. The findings of translational research from the interest study suggests that molecular analyses could not identify a subgroup of patients with improved os on an egfr tki or second-line chemotherapy 55 . It is therefore reasonable to consider an egfr tki as either second-or third-line therapy in the treatment of patients with advanced nsclc. Data from the tailor 100 trial, performed only in patients with wild-type EGFR, demonstrated improved pfs and os when patients received docetaxel chemotherapy (compared with erlotinib). That trial did not allow crossover between the treatment arms, thus denying patients a previously established therapy. Those data therefore do not alter treatment recommendations at this time. The data concerning the combination of an egfr tki with either chemotherapy or another targeted agent are inconsistent. Some promising data have emerged from randomized phase ii trials, but they require confirmation in phase iii trials. Combination therapy with an egfr tki in the second-or third-line setting is therefore not recommended at this time.
Current data do not support the routine use of an egfr tki after disease progression on therapy with another egfr tki. Although data from the lux-Lung 1 trial demonstrated a significant improvement in pfs in a select subgroup of patients, that trial did not meet its primary objective of improved os 99 . Given the absence of improved survival, therapy with afatinib after progression on another egfr tki is not recommended.
The egfr tkis have also been evaluated as switchmaintenance therapy. The saturn trial demonstrated improved os in patients receiving maintenance erlotinib 104 . Interestingly, that benefit was observed whether the patients were EGFR mutation-positive or EGFR wild-type. No molecular marker could identify patients in whom a survival benefit was not observed. The magnitude of the benefit was modest, and other available maintenance therapy strategies should be considered. Nevertheless, there are data to support maintenance therapy with erlotinib after 4 cycles of platinum-based chemotherapy.
Lastly, it is evident from this review that determination of EGFR mutation status is essential to make appropriate treatment decisions. Patients who are EGFR mutation-positive should be treated with an egfr tki as first-line therapy. An egfr tki is still appropriate therapy in patients who are EGFR wild-type, but it should be administered as second-or third-line therapy.
